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PARK2, also known as parkin, is a gene mutated in autosomal recessive juvenile 
parkinsonism and it has been shown to exhibit E3 ubiquitin ligase activity. However 
it seems to fulfill also a wide spectrum of protective functions. Recent studies have 
demonstrated that parkin is an important regulator of process that maintain mito-
chondrial quality and it is also implicated in proteasomal degradation of toxic sub-
strates. This gene has been also shown to be genetically altered and/or aberrantly 
expressed in a wide variety of human cancers including lung cancer (Cesari et al., 
2003; Veeriah S. et al., 2010). Although many alternatively spliced  isoforms have been 
identified, until now studies have been focused on the full-length isoform (D’Agata 
and Cavallaro, 2004). To characterize the role of parkin isoforms in lung tumorigene-
sis we analyzed their expression pattern in human lung adenocarcinomas. These data 
were correlated to their expression pattern either in human lung epithelial carcinoma 
(A549) or in human normal bronchial epithelial (BEAS-2B) cell lines. Western blot and 
immunofluorescence analyses were performed by using two antibodies recognizing 
different domains of the full length protein.
Immunoblots showed that lung adenocarcinomas express parkin isoforms of 50, 
37 and 20 kDa. Their expressions were significantly increased in A549 as compared 
to BEAS-2B, suggesting that parkin isoforms might be involved in cancer progres-
sion. In order to characterize some functions of these isoforms, both cell lines were 
cultured in complete medium or serum starved medium and treated with the pro-
teasome inhibitor MG132 or with carbonyl cyanide 3- clorophenylhydrazone (CCCP), 
a uncoupling agent that dissipates the mitochondrial membrane. Data obtained 
revealed that each treatment affects pattern expression of parkin isoforms. These 
results suggest that some parkin isoforms might be molecular markers of lung adeno-
carcinoma.
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